KYNB — Kyntra Bio, Inc.

Kyntra Bio, Inc. Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Q4 2025 Revenue: $1.3 million, down from $3.1 million in Q4 2024.
• Full Year 2025 Revenue: $6.4 million, significantly decreased from $29.6 million in 2024.
• Q4 2025 Operating Costs: $14.8 million, up from $10.3 million in Q4 2024.
• Full Year 2025 Operating Costs: $52.3 million, down from $180 million in 2024.
• R&D Expenses: Q4 2025 at $7.3 million (up from $6.9 million in Q4 2024); Full Year 2025 at $23.5 million (down from $95.7 million in 2024).
• SG&A Expenses: Q4 2025 at $7.3 million (down from $8.3 million in Q4 2024); Full Year 2025 at $27.7 million (down from $49.3 million in 2024).
• Net Loss: Q4 2025 net loss of $14.6 million ($3.61 per share), compared to a loss of $8.7 million ($2.15 per share) in Q4 2024. Full Year 2025 net loss was $58.2 million ($14.40 per share), improved from a loss of $153.1 million ($38.26 per share) in 2024.
• Cash Position: As of December 31, 2025, cash and equivalents totaled $109.4 million, with a projected cash runway extending into 2028.

2. Strategic Updates and Business Highlights

• Transformational Year: Successfully sold FibroGen China to AstraZeneca, paid off senior secured term loan, and rebranded to Kyntra Bio, Inc.
• FG-3246 Development: Initiated a Phase 2 trial for FG-3246 in metastatic castration-resistant prostate cancer (mCRPC), with promising early results from a Phase 1b/2 trial showing a median radiographic progression-free survival (rPFS) of 10.1 months in certain patient cohorts.
• Roxadustat Progress: Submitted Phase 3 protocol for roxadustat targeting anemia in lower-risk myelodysplastic syndromes (MDS) and received Orphan Drug Designation, with trial initiation expected in the second half of 2026.

3. Forward Guidance and Outlook

• Clinical Milestones: Anticipate interim analysis results from the Phase 2 monotherapy trial for FG-3246 in 2026 and feedback from the FDA on the roxadustat trial design soon.
• Market Potential: FG-3246 is positioned as a first-in-class treatment targeting CD46 in mCRPC, with a total addressable market estimated at over $5 billion annually in the U.S.

4. Bad News, Challenges, or Points of Concern

• Declining Revenue: Significant drop in both quarterly and annual revenues compared to previous years raises concerns about market traction and product uptake.
• Increased Operating Costs: Although overall operating costs decreased year-over-year, Q4 2025 costs rose, indicating potential inefficiencies or increased spending in certain areas.
• Net Losses: Continued substantial net losses, although improved from prior year, highlight ongoing financial challenges.
• Competitive Landscape: The company faces competition from established PSMA-targeted therapies, which may impact the adoption of FG-3246 and its companion diagnostic.

5. Notable Q&A Insights

• Imaging and Commercial Strategy: Discussion on the potential positioning of CD46 PET imaging agents in relation to existing PSMA agents, with a focus on how to integrate into treatment protocols.
• Patient Selection: Insights into the ongoing debate among key opinion leaders regarding the utility of SUV metrics for patient selection in clinical trials, indicating a need for further clarity in defining CD46 positivity.
• Roxadustat Development: Clarification on the timeline for FDA feedback regarding the Phase 3 trial protocol, with expectations set for a response within 60 to 90 days due to the nature of the submission.

This summary encapsulates the key elements from Kyntra Bio's Q4 2025 earnings call, highlighting financial performance, strategic initiatives, outlook, and notable discussions from the Q&A session.